CR20210342A - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
CR20210342A
CR20210342A CR20210342A CR20210342A CR20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A
Authority
CR
Costa Rica
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
thrombotic
Prior art date
Application number
CR20210342A
Other languages
English (en)
Inventor
Martina Schäfer
Pascal Ellerbrock
Kersten Matthias Gericke
Stefan Heitmeier
Adrian Tersteegen
Xianghai Meng
Alexander Hillisch
Katharina Meier
Jan Stampfuss
Hongping Wang
Zengqiang Zou
Sonja Anlauf
Susanne Röhrig
Sebastian Essig
Thomas Neubauer
Dieter Lang
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20210342A publication Critical patent/CR20210342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de oxopiridina sustituidos y a procesos para su preparación, y también a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas.
CR20210342A 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos CR20210342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
CR20210342A true CR20210342A (es) 2021-08-09

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210342A CR20210342A (es) 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos

Country Status (22)

Country Link
EP (1) EP3898633A1 (es)
JP (1) JP2022514303A (es)
KR (1) KR20210106504A (es)
CN (1) CN113474348A (es)
AR (1) AR117435A1 (es)
AU (1) AU2019407909B2 (es)
BR (1) BR112021009435A2 (es)
CA (1) CA3124220A1 (es)
CL (1) CL2021001613A1 (es)
CO (1) CO2021007908A2 (es)
CR (1) CR20210342A (es)
DO (1) DOP2021000128A (es)
EA (1) EA202191764A1 (es)
EC (1) ECSP21043895A (es)
IL (1) IL283990A (es)
JO (1) JOP20210161A1 (es)
MA (1) MA54521A (es)
MX (1) MX2021007508A (es)
PE (1) PE20211790A1 (es)
SG (1) SG11202104384PA (es)
TW (1) TW202039510A (es)
WO (1) WO2020127504A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006710RA (en) * 2018-03-15 2020-08-28 Bayer Ag Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
MX2023010614A (es) 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
WO2022189278A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CA2918814C (en) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
US10077265B2 (en) * 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10138236B2 (en) * 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
WO2016046164A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197889B1 (de) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
WO2016146606A1 (de) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US20180250280A1 (en) 2015-09-04 2018-09-06 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
JP2022514303A (ja) 2022-02-10
WO2020127504A1 (en) 2020-06-25
AU2019407909B2 (en) 2023-05-25
AU2019407909A1 (en) 2021-05-27
TW202039510A (zh) 2020-11-01
PE20211790A1 (es) 2021-09-09
IL283990A (en) 2021-07-29
CL2021001613A1 (es) 2021-12-03
AR117435A1 (es) 2021-08-04
MA54521A (fr) 2022-03-30
BR112021009435A2 (pt) 2021-08-17
CA3124220A1 (en) 2020-06-25
EA202191764A1 (ru) 2021-10-22
CO2021007908A2 (es) 2021-07-19
JOP20210161A1 (ar) 2023-01-30
ECSP21043895A (es) 2021-07-30
EP3898633A1 (en) 2021-10-27
MX2021007508A (es) 2021-08-05
DOP2021000128A (es) 2021-09-30
KR20210106504A (ko) 2021-08-30
CN113474348A (zh) 2021-10-01
SG11202104384PA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CR20210342A (es) Derivados de oxopiridina sustituidos
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12020551973A1 (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2016046156A8 (de) Substituierte oxopyridin-derivate
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PH12021550872A1 (en) Therapeutic compounds
TN2016000107A1 (en) Substituted phenylalanine derivatives
MY150931A (en) Substituted oxazolidinones and their use
JOP20170113B1 (ar) مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2021004860A (es) Piridazinas novedosas.
WO2015165933A3 (de) Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
TN2015000523A1 (en) Substituted benzoxazoles
DOP2024000024A (es) Derivados de s-alaninato sustituidos
AU2016224843A8 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders